Last reviewed 2026-04-23 · How we verify

ALK Alutard 5-grasses

ALK Alutard 5-grasses is an immunotherapy that targets the CD25 antigen.

ALK Alutard 5-grasses is an immunotherapy that targets the CD25 antigen. Used for Allergic rhinitis, Asthma.

At a glance

Mechanism of action

ALK Alutard 5-grasses works by binding to the CD25 antigen, which is a subunit of the IL-2 receptor. This binding prevents IL-2 from binding to its receptor, thereby inhibiting T-cell activation and proliferation. This mechanism is thought to be beneficial in treating various conditions, including allergic diseases.

Approved indications

• Allergic rhinitis
• Asthma

Common side effects

• Injection site reaction
• Headache
• Fatigue
• Nausea

Key clinical trials

• Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass (PHASE1, PHASE2)
• Intralymphatic Immunotherapy in Increasing Doses, Substudy (PHASE2, PHASE3)
• The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma (PHASE2, PHASE3)
• Is Intralymphatic Allergen Immunotherapy Effective and Safe? (PHASE2, PHASE3)
• Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy (PHASE2, PHASE3)
• Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ALK Alutard 5-grasses CI brief — competitive landscape report
• ALK Alutard 5-grasses updates RSS · CI watch RSS
• Lars Olaf Cardell portfolio CI